<?xml version="1.0" encoding="UTF-8"?>
<p id="par0080">Out the list of therapeutic drugs reported the antibiotic azithromicyn added to the anti-malaria drug hydroxychloroquine is used in clinical trials in Marseille, France and some parts of US. Important information needs to be added to the use of these therapies. During the submission of the revised version of this Opinion Paper the US National Institute of Allergy and Infectious Disease (NIAID) did question the use of hydroxychloroquine as drug therapy. Also recently Ivermectin, an FDA-approved anti-parasitic previously shown to have broad spectrum anti-viral activity 
 <italic>in vitro</italic>, was shown to be an inhibitor of COVID-19 [
 <xref rid="bib0150" ref-type="bibr">30</xref>]. Certainly Ivermectin therefore warrants further investigation for possible benefits in humans. In the meantime these pharmaceuticals are beneficials for humans waiting for the vaccine to come.
</p>
